Show the full website


Novo Holdings raises stakes on Zealand Pharma competitor – joins million-dollar investment

Once again, Novo Ventures posts millions of dollars in newly founded spinout company Vectivbio, which is developing a treatment for short bowel syndrome. This time, the Danish venture fund joins a USD 110m investment in the firm, which plans to challenge Zealand Pharma with its drug.

Partner at Novo Ventures Naveed Siddiqi | Foto: Novo Holdings / PR

Recently founded spinout company Vectivbio has landed a USD 110m investment from both existing investors and newcomers.

Amongst the former are Novo Ventures, which joined a consortium of major investors that posted DKK 235m (USD 37.2m) into Vectivbio at the start of the year, after having developed a liking for the firm and its drug apraglutide, which has recently showed promising results during phase II trials for treating short bowel syndrome.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Receive newsletter from MedWatch today

NB: Subscribing to the newsletter is free.

More from MedWatch


See all jobs